Cubist Forges Antibiotic Deal With B-MS
Bristol-Myers Squibb has entered into a research collaboration with Cubist Pharmaceuticals for the development of new antibacterial and antifungal agents. The deal is worth up to $56 million to Cubist, which has already received equity investment of $4 million and a first milestone payment.
The focus of the collaboration will be the development of inhibitors of Cubist's aminoacyl-tRNA synthetases, a family of 20 enzymes essential to the process of protein translation (Marketletter January 22). This is the second major collaboration for Cubist, which is already working with Pfizer.
The first milestone related to the development and transferral of technology to B-MS to allow the firm to screen for potential compounds. The $56 million depends upon the two firms' bringing one antifungal, an antituberculosis drug and an antibacterial to market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze